Shuttle Pharmaceuticals (SHPH) shares saw a dip despite receiving a new patent for its selective histone deacetylase (HDAC) inhibitors. The patent covers inhibitors designed to fight cancer and other diseases. Despite earlier gains, the stock is currently trading lower. Benzinga explores the factors investors should consider when evaluating SHPH as a potential investment.
The HDAC inhibitors market has witnessed significant growth in recent years, driven by the promising therapeutic potential of these drugs in treating a wide range of diseases, particularly cancer and neurological disorders. HDAC inhibitors are a class of compounds that modulate gene expression by inhibiting the activity of histone deacetylases (HDACs), which in turn plays a crucial role in regulating gene expression. This regulatory mechanism has led to the exploration of HDAC inhibitors as potential therapeutic agents for various diseases, with a focus on oncology and neurology.
